Powering protein degradation for tomorrow’s medicines. "We are changing the limits of what is possible in medicine. Our vision is to provide a remedy for debilitating diseases that lack effective treatments."Ying Luo, Ph.D. - C.E.O. More About Us Expanding the drug design paradigm Targeted Protein Degraders: The ability to drug the “undruggable.” Learn About the Science uSMITE™ Our innovative protein degradation technology featuring novel E3 ligands. Our Platform We build the world’s most robust protein degraders using our novel E3 ligands for the treatment of cancer and other debilitating diseases. Our Pipeline Latest News November 13, 2024 PULMATRIX AND CULLGEN ANNOUNCE PROPOSED MERGERClick here to access webcast October 8, 2024 CULLGEN ANNOUNCES CHINESE NMPA ALLOWANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CG009301, A HIGHLY SELECTIVE GSPT1 DEGRADER January 16, 2024 CULLGEN ANNOUNCES ADDITIONS TO BOARD OF DIRECTORS AND SCIENTIFIC ADVISORY BOARD See All